UNIVEST FINANCIAL Corp Sells 16,141 Shares of Pfizer Inc. (NYSE:PFE)

UNIVEST FINANCIAL Corp decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 34.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,505 shares of the biopharmaceutical company's stock after selling 16,141 shares during the period. UNIVEST FINANCIAL Corp's holdings in Pfizer were worth $809,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the 4th quarter valued at $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the fourth quarter worth $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.8 %

Shares of PFE traded up $0.19 during midday trading on Friday, hitting $25.20. The stock had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The firm has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a 50 day simple moving average of $26.06 and a two-hundred day simple moving average of $26.92. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and an average price target of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.